# US 2021/0061789 A1 · Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061789 A1
- Document ID: US20210061789A1
- Status: Published application
- Kind: A1
- Application number: 16/958,066
- Filed: 2018-12-26
- Published: 2021-03-04
- Earliest claimed: 2017-12-27
- Assignees: Riken; Japanese Foundation for Cancer Research; Kabushiki Kaisha Yakult Honsha
- Applicants: Riken; Japanese Foundation for Cancer Research; Kabushiki Kaisha Yakult Honsha
- Inventors: Minoru YOSHIDA; Hiroyuki SEIMIYA; Yoko YASHIRODA; Kenichi WASHIZUKA; Fumiyuki SHIRAI; Nobuko YOSHIMOTO; Junichi KAZAMI
- Web page: https://patentgrep.com/patent/US20210061789A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/06: Peri-condensed systems
- C07D 498/06: Peri-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH; r represents 0 to 4; each R101 is the same or different when r is 2 or more, and R101 represents a C1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R102 is the same or different when s is 2 or more, and R102 represents a halogen atom or the like; R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A composition comprising a compound of the following formula (1) or a pharmacologically acceptable salt thereof:
wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH:
r represents 0 to 4;
each R101 is the same or different when r is 2 or more, and represents a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, OR111, or a group represented by the formula: —N(R112a)—R112a,
where R111, R112a and R112b are each independently a hydrogen atom or a C1-6 alkyl group;
s represents 0 to 5;
each R102 is the same or different when s is 2 or more, and represents a halogen atom, a C1-6 alkyl group, OR113, a group represented by the formula —N(R114a)—R114b, a group represented by the formula: —NH—C(═O)—R115, a group represented by the formula: —C(═O)—R116, an optionally substituted aryl group, an optionally substituted heteroaryl group, a nitro group, or a cyano group,
where R113 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted arylalkyl group, or an optionally substituted heteroaryl group,
R114a and R114b are each independently a hydrogen atom or a C1-6 alkyl group,
R115 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a group represented by the formula: —NH—R121,
R116 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, OR122, or a group represented by the formula: —N(R123a)—R123b,
R121 is an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group,
R122 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, and
R123a and R123b are each independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or R123a and R123b are linked together to form a cyclic amine;
R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and
R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position; and
a diluent or a pharmaceutically acceptable excipient.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the compound of the formula (1) is a compound of the following formula (1a):
wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH;
r represents 0 to 4;
each R101 is the same or different when r is 2 or more, and represents a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, OR111, or a group represented by the formula: —N(R112a)—R112b,
where R111, R112a and R112b are each independently a hydrogen atom or a C1-6 alkyl group;
s represents 0 to 5;
each R102 is the same or different when s is 2 or more, and represents a halogen atom, a C1-6 alkyl group, OR113, a group represented by the formula —N(R114a)—R114b, a group represented by the formula: —NH—C(═O)—R115, a group represented by the formula: —C(═O)—R116, an optionally substituted aryl group, an optionally substituted heteroaryl group, a nitro group, or a cyano group,
where R113 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted arylalkyl group, or an optionally substituted heteroaryl group,
R114a and R114b are each independently a hydrogen atom or a C1-6 alkyl group,
R115 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a group represented by the formula: —NH—R121,
R116 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, OR122, or a group represented by the formula: —N(R123a)—R123b,
R121 is an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group,
R122 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, and
R123a and R123b are each independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or R123a and R123b are linked together to form a cyclic amine;
R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and
R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position,
with the exception of cases where J1 represents CH, J2 represents N, r is 0, R103 is a hydrogen atom or a methyl group, R102 is present at the p-position, and R102 is a methoxy group.

### Claim 22 (depends on 20)

The composition of claim 20, wherein in formula (1), r is 0; or r is 1, R101 is present at the 7-position or the 8-position and R101 represents a C1-3 alkyl group optionally substituted with a halogen atom, or a hydroxy group; or r is 1, R101 is present at the 8-position and R101 and R103 are linked together to form a five- or six-membered ring hetero ring.

### Claim 23 (depends on 20)

The composition of claim 20, wherein in formula (1) R103 represents a hydrogen atom, a C1-3 alkyl group or a C3-6 cycloalkyl C1-3 alky group; or r is 1, R101 is present at the 8-position and R101 and R103 are linked together to form a five- or six-membered ring hetero ring.

### Claim 24 (depends on 20)

The composition of claim 20, wherein in formula (1), s is 0; or s is 1 and R102 represents a halogen atom, OR113 in which R113 is an optionally substituted C1-3 alkyl group, or an optionally substituted aryl group.

### Claim 25 (depends on 20)

The composition of claim 20, wherein in formula (1), J1 and J2 each represent N.

### Claim 26

A method for inhibiting cell proliferation, the method comprising contacting a cell with a compound of the following formula (1) or a pharmacologically acceptable salt thereof:
wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH;
r represents 0 to 4;
each R101 is the same or different when r is 2 or more, and represents a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, OR111, or a group represented by the formula: —N(R112a)—R112b,
where R111, R112a and R112b are each independently a hydrogen atom or a C1-6 alkyl group;
s represents 0 to 5;
each R102 is the same or different when s is 2 or more, and represents a halogen atom, a C1-6 alkyl group, OR113, a group represented by the formula —N(R114a)—R114b, a group represented by the formula: —NH—C(═O)—R115, a group represented by the formula: —C(═O)—R116, an optionally substituted aryl group, an optionally substituted heteroaryl group, a nitro group, or a cyano group,
where R113 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted arylalkyl group, or an optionally substituted heteroaryl group,
R114a and R114b are each independently a hydrogen atom or a C1-6 alkyl group,
R115 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a group represented by the formula: —NH—R121,
R116 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, OR122, or a group represented by the formula: —N(R123a)—R123b,
R121 is an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group,
R122 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, and
R123a and R123b are each independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or R123a and R123b are linked together to form a cyclic amine;
R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and
R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position; and
a diluent or a pharmaceutically acceptable excipient.

### Claim 27 (depends on 26)

The method of claim 26, wherein the compound of the formula (1) is a compound of the following formula (1a):
wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH;
r represents 0 to 4;
each R101 is the same or different when r is 2 or more, and represents a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, OR111, or a group represented by the formula: —N(R112a)—R112b,
where R111, R112a and R112b are each independently a hydrogen atom or a C1-6 alkyl group;
s represents 0 to 5;
each R102 is the same or different when s is 2 or more, and represents a halogen atom, a C1-6 alkyl group, OR113, a group represented by the formula —N(R114a)—R114b, a group represented by the formula: —NH—C(═O)—R115, a group represented by the formula: —C(═O)—R116, an optionally substituted aryl group, an optionally substituted heteroaryl group, a nitro group, or a cyano group,
where R113 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted arylalkyl group, or an optionally substituted heteroaryl group,
R114a and R114b are each independently a hydrogen atom or a C1-6 alkyl group,
R115 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a group represented by the formula: —NH—R121,
R116 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, OR122, or a group represented by the formula: —N(R123a)—R123b,
R121 is an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group,
R122 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, and
R123a and R123b are each independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or R123a and R123b are linked together to form a cyclic amine;
R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and
R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position,
with the exception of cases where J1 represents CH, J2 represents N, r is 0, R103 is a hydrogen atom or a methyl group, R102 is present at the p-position, and R102 is a methoxy group.

### Claim 28 (depends on 26)

The method of claim 26, wherein in formula (1), r is 0: or r is 1, R101 is present at the 7-position or the 8-position and R101 represents a C1-3 alkyl group optionally substituted with a halogen atom, or a hydroxy group; or r is 1, R101 is present at the 8-position and R101 and R103 are linked together to form a five- or six-membered ring hetero ring.

### Claim 29 (depends on 26)

The method of claim 26, wherein in formula (1), R103 represents a hydrogen atom, a C1-3 alkyl group or a C3-6 cycloalkyl C1-3 alky group: or r is 1, R101 is present at the 8-position and R101 and R103 are linked together to form a five- or six-membered ring hetero ring.

### Claim 30 (depends on 26)

The method of claim 26, wherein in formula (1), s is 0; or s is 1 and R102 represents a halogen atom, OR113 in which R113 is an optionally substituted C1-3 alkyl group, or an optionally substituted aryl group.

### Claim 31 (depends on 26)

The method of claim 26, wherein in formula (1), J1 and J2 each represent N.

### Claim 32 (depends on 26)

The method of claim 26, comprising inhibiting tankyrase by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 33 (depends on 27)

The method of claim 27, comprising inhibiting tankyrase by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 34 (depends on 26)

The method of claim 26, comprising inhibiting microtubules by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 35 (depends on 27)

The method of claim 27, comprising inhibiting microtubules by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 36 (depends on 26)

The method of claim 26, comprising treating a disease attributable to tankyrase and/or microtubules by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 37 (depends on 27)

The method of claim 27, comprising treating a disease attributable to tankyrase and/or microtubules by administering the compound of the formula (1) or a pharmacologically acceptable salt thereof to a patient in need thereof.

### Claim 38 (depends on 36)

The method of claim 36, wherein the disease is selected from the group consisting of malignant tumor, Herpes simplex virus infection, Epstein-Barr virus infection, pulmonary fibrosis, multiple sclerosis and amyotrophic lateral sclerosis.

### Claim 39

A compound of the following formula (1a) or a pharmacologically acceptable salt thereof:
wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH;
r represents 0 to 4;
each R101 is the same or different when r is 2 or more, and represents a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, OR111, or a group represented by the formula: —N(R112a)—R112a,
where R111, R112a and R112b are each independently a hydrogen atom or a C1-6 alkyl group;
s represents 0 to 5;
each R102 is the same or different when s is 2 or more, and represents a halogen atom, a C1-6 alkyl group, OR113, a group represented by the formula —N(R114a)—R114b, a group represented by the formula: —NH—C(═O)—R115, a group represented by the formula: —C(═O)—R116, an optionally substituted aryl group, an optionally substituted heteroaryl group, a nitro group, or a cyano group,
where R113 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted arylalkyl group, or an optionally substituted heteroaryl group,
R114 and R114b are each independently a hydrogen atom or a C1-6 alkyl group,
R115 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a group represented by the formula: —NH—R121,
R116 is an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, OR122, or a group represented by the formula: —N(R123a)—R123b,
R121 is an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group,
R122 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, and
R123a and R123b are each independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or R123a and R123b are linked together to form a cyclic amine;
R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and
R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position,
with the exception of cases where J1 represents CH, J2 represents N, r is 0, R103 is a hydrogen atom or a methyl group, R102 is present at the p-position, and R102 is a methoxy group.
